Who
Jude Onyia
Chief Scientific Officer
Company insider
Files Form 4 as: Chief Scientific Officer, Neurocrine Biosciences; Director, Voyager Therapeutics.
In numbers
- Trades disclosed
- 100
- Buys
- 0
- Sells
- 14
- Bought
- $0
- Sold
- $19.6M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 29 Nov 2021
- Last trade
- 11 Sep 2026
- Last filed
- 15 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code A | —3,587 at $0.00 | filing |
| 11 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code F | $302K1,936 at $156.22 | filing |
| 11 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code A | —3,587 at $0.00 | filing |
| 11 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code F | $302K1,936 at $156.22 | filing |
| 4 Aug 2026filed 5 Aug 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code G | —2,409 at $0.00 | filing |
| 4 Aug 2026filed 5 Aug 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code G | —2,409 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | VYGR Voyager Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | VYGR Voyager Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code G | —2,441 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code G | —2,441 at $0.00 | filing |
| 1 Jun 2026filed 2 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | $932K11,000 at $84.74 | filing |
| 1 Jun 2026filed 2 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $1.8M11,000 at $160.25 | filing |
| 1 Jun 2026filed 2 Jun 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —11,000 at $0.00 | filing |
| 1 Jun 2026filed 2 Jun 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —11,000 at $0.00 | filing |
| 1 Jun 2026filed 2 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | $932K11,000 at $84.74 | filing |
| 1 Jun 2026filed 2 Jun 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $1.8M11,000 at $160.25 | filing |
| 27 May 2026filed 29 May 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | $932K11,000 at $84.74 | filing |
| 27 May 2026filed 29 May 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $1.7M11,000 at $155.53 | filing |
| 27 May 2026filed 29 May 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —11,000 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —11,000 at $0.00 | filing |
News
Contrasting Neurocrine Biosciences (NASDAQ:NBIX) and Perrigo (NYSE:PRGO)NBIX · dailypolitical.com · 10 Oct 2026
0 headlines in the last 90 days name Jude Onyia; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.